Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46.2 -0.4 (-0.86%) Market Cap: 4.31 Bil Enterprise Value: 3.76 Bil PE Ratio: 0 PB Ratio: 13.42 GF Score: 81/100

Q4 2019 Ultragenyx Pharmaceutical Inc Earnings Call Transcript

Feb 13, 2020 / 10:00PM GMT
Release Date Price: €57.5 (+0.88%)
Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Ultragenyx Fourth Quarter and Full Year 2019 Financial Results Conference Call. (Operator Instructions)

I would now like to hand the conference to your speaker today, Danielle Keatley. Please go ahead.

Danielle Keatley
Ultragenyx Pharmaceutical Inc. - Senior Director of IR & Corporate Communications

Thank you. Good afternoon, and welcome to the Ultragenyx Pharmaceutical financial results and corporate update conference call for the fourth quarter and full year 2019. We've issued a press release detailing our financial results, which you can find on our website at ultragenyx.com.

I'm Danielle Keatley, Senior Director of Investor Relations. And with me today are Emil Kakkis, Chief Executive Officer and President; and Shalini Sharp, Chief Financial Officer.

I'd like to remind investors that this call will include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot